Related by context. All words. (Click for frequent words.) 61 phase IIb trial 61 rALLy trial 61 phase III ACCLAIM 61 STRIDE PD 61 ENRICH trial 60 phase IIb clinical 60 phase IIa clinical 60 Phase IIa clinical trials 60 SYMMETRY trial 60 phase IIa 60 CLIRS trial 59 EMPOWER ™ 59 riociguat 59 PRECISE trial 59 PRIMO CABG2 59 PNH patients 59 NATRECOR R 59 IIb clinical trial 58 BRIM2 58 Phase 2b study 58 PROactive study 58 EchoCRT 58 CARE HF 58 Phase IIa trial 58 MEND CABG 58 clazosentan 58 SUCCEED trial 58 EMPOWER TM 58 ruxolitinib 58 opioid induced bowel dysfunction 58 Viprinex TM 58 phase IIIb 58 Phase #b/#a 57 GENASIS trial 57 Ocrelizumab 57 Phase 2a clinical 57 CRMD# 57 Phase IIB 57 coronary revascularization 57 EMPHASIS HF trial 57 Phase III VISTA 57 PFO migraine 57 placebo controlled Phase III 57 number NCT# ClinicalTrials.gov 57 MERLIN TIMI 57 HCV RESPOND 2 57 PROTECT II 57 Phase #b/#a clinical 57 ANCHOR trial 57 ADVANCE PD 57 Trofex 57 clinical pharmacology studies 57 VITAL Trial 57 MIST II 56 dexanabinol 56 warfarin therapy 56 Octreolin 56 Urocortin 2 56 Celacade TM 56 prospective multicenter study 56 OPT CHF 56 composite endpoint 56 Fibrillex TM 56 MYDICAR 56 angiographic outcomes 56 PRIMO CABG 56 Phase #/#a trial 56 clinical trial 56 randomized Phase IIb 56 CEQ# 56 BrachySil TM 56 rALLy clinical trial 56 Zenvia ™ 56 Phase IIb trials 56 Sulonex TM 56 CHAMPION PCI 56 myelofibrosis 56 multicenter prospective 56 Phase Ib clinical 56 teriflunomide 56 Dacogen injection 56 BRIM3 56 MADIT II 56 Asentar 56 ELACYT 56 trial evaluating PRX# 56 percutaneous cryoablation 56 severe hypercholesterolemia 56 IMPACT DCM 55 Phase Ib study 55 BLA filing 55 PRNewswire FirstCall Genta Incorporated 55 OFIRMEV 55 CLARITY study 55 alvimopan 55 Sulonex 55 clinicaltrials 55 RIO Diabetes 55 pivotal bioequivalence 55 bicifadine 55 Phase IIa clinical 55 INTERCEPT platelets 55 Phase IIb trial 55 phase IIb study 55 ASCEND HF 55 Phase III metastatic melanoma 55 ARCOXIA 55 sNDA submission 55 prospectively defined 55 placebo controlled Phase 55 NSABP C 55 PROPEL trial 55 Zemplar Capsules 55 Zenvia Phase III 55 clevidipine 55 registrational 55 SUTENT ® 55 Androxal TM 55 thorough QT 55 clinical trials 55 secondary efficacy endpoint 55 confirmatory Phase III 55 MTWA testing 55 Phase IIIb clinical 55 PROMACTA 55 Phase Ib IIa 55 PEG PAL 55 KRN# 55 ATACAND 55 TAXUS VI 55 placebo controlled clinical 55 multicenter trials 55 multicenter Phase II 55 IMPACT DCM clinical 55 Stedivaze 55 phase IIb 54 EFAPROXYN 54 tanespimycin 54 ACUITY trial 54 Val HeFT 54 AZD# TC 54 lorcaserin Phase 54 lomitapide 54 darusentan 54 oral ridaforolimus 54 omecamtiv mecarbil 54 oral FTY# 54 INCB# [001] 54 Zemiva TM 54 nonclinical studies 54 lumiliximab 54 efficacy endpoints 54 tesmilifene 54 NLX P# 54 Phase 2b clinical 54 Phase 2b trial 54 Vernakalant 54 OvaRex ® MAb 54 CombAT 54 MEND CABG II 54 recurrent glioblastoma multiforme 54 oxymorphone ER 54 Phase 1a clinical 54 GEM OS1 54 Rasilez Tekturna 54 rALLy 54 MoxDuo IR 54 midstage clinical trial 54 Fx #A 54 unblind 54 CIMZIA TM certolizumab pegol 54 Allovectin 7 54 NEO3 54 investigational therapies 54 PIX# [002] 54 Phase IIb clinical trials 54 Rezular 54 Phase III randomized controlled 54 Phase 2a trial 54 brivaracetam 54 tafamidis 54 efficacy endpoint 54 Acetavance 54 dose escalation phase 54 BLA submission 54 RE LY ® 54 AVERROES 54 FOLOTYN ® 54 HCV SPRINT 54 APEX AMI trial 54 ADVEXIN clinical 54 CALGB # [002] 54 PEARL SC 54 Phase Ib II 54 confirmatory clinical 54 Auxilium anticipates 54 chemoprevention trials 54 IMPACT IMmunotherapy 53 Dextofisopam 53 lymphadenectomy 53 ENDEAVOR IV 53 Phase IIb clinical 53 relapsed MCL 53 acute decompensated heart 53 reduce serum phosphate 53 Elocalcitol 53 HORIZONS AMI trial 53 IRX 2 53 Thorough QT 53 IL# PE#QQR 53 glufosfamide 53 Phase 2a clinical trials 53 Proellex TM 53 Azedra ™ 53 PRECISE Trial 53 ACTEMRA TM 53 nonrandomized 53 Phase III trials 53 multicenter Phase 53 bardoxolone methyl 53 AIR2 Trial 53 IIa trial 53 dirucotide 53 Prostate AdenoCarcinoma Treatment 53 Phase III pivotal 53 RIGScan CR 53 oral methylnaltrexone 53 SIMPADICO 53 T Pred 53 enoximone capsules 53 REMINYL ® 53 EVEREST II 53 VALOR trial 53 talactoferrin 53 Phase IIIb 53 MYCAMINE 53 COSIRA trial 53 alvespimycin 53 placebo controlled clinical trials 53 modified REGENESIS Phase IIb 53 Omigard 53 resultsof 53 perioperative mortality 53 MAGE A3 ASCI 53 REG1 53 BETAS 53 iii GTx 53 Phenoptin 53 forodesine 53 AIM HIGH 53 Aryplase 53 APPRAISE 53 SuperMedia specializes 53 prospective multicentre 53 rolofylline 53 retrospective observational study 53 APEX PD 53 RSD# oral 53 safinamide 53 R0 resection 53 GEM OS2 53 randomized Phase 2b 52 midstage trials 52 recurrent malignant glioma 52 Adentri 52 Pivotal Clinical Trial 52 COMFORT II 52 ACC AHA ESC 52 GALNS 52 alogliptin 52 ularitide 52 pivotal Phase III 52 methylnaltrexone tablet 52 diabetic neuropathic pain 52 Allovectin 7 ® 52 ACCEDE 52 GRAVITAS trial 52 CTAP# Capsules 52 Phase IIb III 52 CAMMS# 52 Phase 2b monotherapy 52 Topical Interferon Alpha 2b 52 QTinno TM 52 prespecified secondary 52 elotuzumab 52 motesanib 52 eltrombopag 52 SNT MC# 52 Phase #b/#a trial 52 phase Ib 52 ALSYMPCA 52 otelixizumab 52 MADIT CRT 52 dirucotide MBP# 52 TOLAMBA 52 Committee IDMC 52 dose escalation clinical 52 Kynapid 52 Phase 1b clinical 52 vosaroxin 52 AVOREN 52 Phase 1b 52 multicenter Phase III 52 IIa clinical 52 Corlux 52 Phase III clinical 52 PREOS 52 AVN# Phase 52 Phase #/#a 52 midstage clinical trials 52 SILENOR 52 GAMMAGARD 52 ENDEAVOR III 52 HepeX B 52 Fabry Disease 52 Phase Ib clinical trials 52 CardioFit 52 histone deacetylase HDAC inhibitor 52 SinuNase TM 52 AeroLEF TM 52 CHAMPION PLATFORM 52 EndoTAG TM -1 52 Hepatocellular Carcinoma HCC 52 LUMINATE 52 postapproval 52 landmark ATHENA 52 randomized multicenter 52 olaparib 52 Phase III clinical trials 52 midstage studies 52 maribavir 52 ENDEAVOR II 52 ATL# [001] 52 Phase Ib 52 Motesanib 52 IMPROVE HF 52 dacetuzumab 52 AQ4N 52 EDEMA3 trial 52 #mg dose [002] 52 Zemiva ™ 52 Entereg TM 52 BCIRG 52 elagolix 52 Telintra 52 ProSavin 52 bardoxolone 52 Phase IIa trials 52 AERx iDMS 52 Plenaxis TM 52 Phase III 52 prognostic variables 52 Dose escalation 52 pharmacokinetic PK study 52 BR.# 52 apremilast 52 LibiGel Phase III 52 PANVAC VF 52 Cloretazine 52 echocardiographic parameters 52 Phase 2b randomized 52 novel VDA molecule 52 NP2 Enkephalin 52 dose escalation Phase 52 Phase 1b clinical trials 52 PDX pralatrexate 52 UKPDS 52 secondary efficacy endpoints 52 Plicera 52 TG MV 52 Fast Tracked Phase 51 carotid endarterectomy CEA 51 Phase III TRIST 51 TBC# 51 torcetrapib atorvastatin 51 affecting Pennichuck Corporation 51 ataluren 51 Glybera R 51 Phase IIIb study 51 NEVO ™ 51 CVBT #H 51 Cloretazine R VNP#M 51 TELINTRA 51 placebo controlled randomized 51 dosing cohort 51 Proxinium TM 51 Phase 1b trial 51 Microplasmin 51 Augment Injectable 51 intravesical therapy 51 carcinogenicity study 51 oral deforolimus 51 RE LY 51 ruboxistaurin 51 evaluating REVLIMID 51 AEGR 51 PreCISe 51 Medidur TM FA 51 cannabinor 51 Advagraf 51 metastatic renal cell 51 randomized multicenter Phase III 51 TEMSO 51 SEPET TM 51 ONTARGET 51 carotid stenosis 51 RhuDex ® 51 ThermoDox R 51 postoperative mortality 51 SCD HeFT 51 Tocosol Paclitaxel 51 Phase III HEAT 51 selective androgen receptor modulator 51 multicenter placebo controlled 51 SIMPADICO trial 51 Diabetic Macular Edema 51 prospective randomized placebo 51 SPIRIT IV 51 Removab 51 torezolid phosphate 51 Phase III psoriasis 51 metastatic sarcomas 51 MOZOBIL 51 arzoxifene 51 ARISE Phase III 51 ocrelizumab 51 eprotirome 51 fosbretabulin 51 European Sepsis Trial 51 Prestara 51 Secondary efficacy endpoints 51 compound INCB# 51 XL# SAR# 51 EmbraceAC 51 NV1FGF 51 Pivotal Trial 51 Phase 2b kidney transplant 51 clinical endpoints 51 TQT studies 51 Phase III Pivotal 51 Archexin 51 CUSTOM III 51 Triolex 51 Puricase PEG uricase 51 Virulizin R 51 RE LY trial 51 cardio renal 51 multicenter study 51 OvaRex R 51 multicenter multinational 51 ICON7 51 Amrubicin 51 tezampanel NGX# 51 rEV# 51 ATPace TM 51 ReN# 51 SPARLON 51 MGd 51 MyVax personalized immunotherapy 51 OncoGel 51 non squamous NSCLC 51 midstage clinical 51 EMPOWER pivotal trial 51 Bicifadine 51 efficacy tolerability 51 Edwards SAPIEN valve 51 MoxDuo TM IR 51 ADAGIO study 51 NEVO RES 51 adjuvant GIST 51 FOLPI 51 myoblast therapy 51 TAXUS TM 51 VADT 51 NEUVENGE 51 Ketotransdel 51 Pivotal Phase III 51 Itopride 51 ASSERT trial 51 phase 2a 51 Actimmune ® 51 Solorel 51 confirmatory Phase 3 51 RELIANT Trial 51 APF# Phase 51 Cutanea 51 ABSORB trial 51 rindopepimut 51 PSN# [002] 51 indiplon capsules 51 Study GL# 51 label dose titration 51 Phase III multicenter 51 ROCKET AF 51 Onalta ™ 51 evaluable subjects 51 LEP ETU 51 Canvaxin 51 Zerenex 51 Puricase 51 haematologic 51 DSMB 51 postoperative complication 51 BrachySil ™ 51 blinded randomized placebo controlled 51 Nuvion 51 #D#C# 50 systemic ALCL 50 Exelixis compounds 50 Phase 1b dose escalation 50 mg/m2 cohort 50 ponatinib 50 DES implantation 50 placebo controlled trials 50 THALOMID 50 Northera 50 Solazed 50 canakinumab 50 Adlea 50 Phase IIa 50 eculizumab therapy 50 Phase III confirmatory 50 ONCONASE R 50 ELADUR 50 subgroup analyzes 50 Troxatyl 50 Renal Cell Carcinoma RCC 50 ZYBRESTAT fosbretabulin 50 darapladib 50 PRX # 50 HeFT 50 randomized blinded 50 PROSTVAC ® 50 postoperative chemotherapy 50 Bezielle 50 GRN# 50 XIENCE V demonstrated 50 Viprinex 50 Phase 2a 50 NO# [002] 50 ZoMaxx 50 IV NSCLC 50 PREOS R 50 Exherin TM 50 antibody MAb 50 CHARM Added 50 prospective randomized multicenter 50 RhuDex 50 renal anemia 50 TAXUS IV 50 bile duct tumor 50 Neuradiab 50 CB2 selective receptor agonist 50 prospective nonrandomized 50 placebo controlled studies 50 celgosivir 50 masked placebo controlled 50 IPLEX 50 Cetrorelix 50 ancrod 50 Excellagen 50 phase Ib clinical 50 evaluating tivozanib 50 LibiGel ® 50 Oncotype DX colon cancer 50 noninvasive outpatient 50 ToGA 50 nalbuphine ER 50 AZILECT R 50 Toraymyxin TM 50 GLP toxicology studies 50 DASISION 50 Bioaccelerate compounds under 50 Cethrin 50 prospective multicenter 50 OMAPRO 50 MERIT ES 50 Prosaptide 50 Azedra 50 adrenocortical cancer 50 trastuzumab DM1 50 YONDELIS 50 COU AA 50 Vicinium TM 50 budesonide foam 50 OLYMPIA registry 50 #rd Annual CTRC 50 SPIRIT FIRST 50 Oral NKTR 50 trials RCTs 50 trial evaluating Prochymal 50 valopicitabine 50 Rheos System 50 ALGRX 50 CYPHER R Sirolimus eluting 50 MAA submission 50 Fibrillex 50 crizotinib PF # 50 intravenous methylnaltrexone 50 dosing cohorts 50 CYT# potent vascular disrupting 50 trastuzumab DM1 T DM1 50 AIR CF2 50 TPI ASM8 50 Onrigin 50 GOUT 50 multicenter randomized controlled 50 ILLUMINATE 50 rheumatoid arthritis osteoarthritis ankylosing 50 zalutumumab 50 Mipomersen 50 velafermin 50 TASKi3 50 RSD# 50 iclaprim 50 FACTIVE tablets 50 Phase IIb 50 prespecified 50 response pCR 50 RIO Lipids 50 refractory AML 50 tramiprosate Alzhemed TM 50 multigene expression test 50 TRISENOX 50 unblinding 50 Cloretazine ® 50 AGILECT ® 50 IMC #B 50 Neo Kidney Augment 50 TELCYTA 50 ritonavir boosted danoprevir 50 EVIZON TM 50 pharmacodynamic effects 50 mRCC 50 randomized controlled clinical trials 50 relapsed SCLC 50 Genz # 50 ORBIT II 50 CURRENT OASIS 7 50 Tavocept 50 adjuvant colon cancer 50 BARI 2D 50 underwent resection 50 Vion Pharmaceuticals 50 fidaxomicin Phase 3 50 Phase III Clinical Trial 50 Cimzia TM 50 dose cohort 50 adverse cytogenetics 50 Onbrez Breezhaler 50 Elagolix 50 ORENCIA R 50 figitumumab 50 CoAxia 50 successfully commercialize Iluvien 50 eptifibatide 50 oral rivaroxaban 50 CA4P 50 pharmacokinetic PK 50 Ereska 50 Aloxi injection 50 Arzerra ofatumumab 50 Panzem R 49 recurrent glioma 49 EORTC 49 JAK inhibitor 49 Aflibercept 49 EOquin 49 tolevamer 49 recurrent GBM 49 pegloticase 49 deforolimus 49 Phase 2b 49 multicenter clinical trials 49 Provecta 49 omacetaxine mepesuccinate 49 HGS ETR2 49 Xanafide 49 Safinamide 49 TLK# 49 sunitinib malate 49 brain metastases originating 49 faropenem 49 including withoutlimitation 49 Desmoteplase 49 VICTOR E1 49 Cleviprex TM clevidipine 49 rNAPc2 49 targeted radiotherapeutic 49 PRECiSE 49 Cardio Vascu Grow 49 Phase 1a 49 refractory Hodgkin lymphoma 49 LEUKINE 49 PSMA ADC 49 ATIR TM 49 beta blocker therapy 49 multicenter clinical 49 CytoFabTM 49 PLK1 SNALP 49 GTC recombinant human 49 reslizumab 49 ENESTnd 49 R#/MEM # 49 QLT# 49 double blinded placebo 49 acute ischemic stroke 49 CRD5 49 Zevalin consolidation 49 Multicenter Automatic Defibrillator Implantation 49 eliglustat tartrate 49 PRE SURGE 49 OHR/AVR# 49 pain palliation 49 pCR 49 pediatric acute lymphoblastic 49 Diamyd r vaccine 49 PCA3 test 49 ZYBRESTAT 49 ARCALYST ® 49 Azixa 49 QTc prolongation 49 neratinib 49 randomized clinical 49 enzastaurin 49 multicenter phase 49 mertansine 49 ALLHAT 49 dose titration 49 rFVIIa 49 SPIRIT III 49 TRITON TIMI 49 denosumab oncology 49 exploratory endpoints 49 IIa trials 49 pralatrexate 49 Ostarine 49 varespladib 49 CAPACITY trials 49 AGGRASTAT ® tirofiban hydrochloride 49 paclitaxel eluting stents 49 sapacitabine 49 PLCO 49 Azedra TM 49 Empatic 49 Zingo TM 49 BCX# 49 substudy 49 AZILECT ® 49 bevasiranib 49 controlled multicenter 49 teduglutide 49 AZX# 49 SABCS 49 registrational trial 49 Clinical Antipsychotic Trials 49 Iluvien 49 Targretin capsules 49 postmenopausal osteoporotic women 49 Solazed TM 49 mipomersen 49 Cinquil 49 pharmacokinetic equivalence 49 Spiegelmer ® 49 TOCOSOL Paclitaxel 49 EDEMA4 49 Amoxicillin PULSYS Phase III 49 Ophena TM 49 obatoclax 49 JAK2 inhibitor 49 viral kinetics 49 elevated uric acid 49 dose escalation 49 PreCISe study 49 dose cohorts 49 Edge STudy 49 lung resection 49 DSMB recommended 49 EVIZON 49 MACCE 49 BGM Galectin 3 49 Urocidin TM 49 GetGoal Phase III 49 genotypic resistance 49 Hedgehog antagonist 49 randomized clinical trials 49 PF # [002] 49 Idenix anticipates 49 Xinlay 49 dimebon 49 Subgroup analysis 49 Genasense ® 49 tumor lysis syndrome 49 CRp 49 active comparator 49 AVADO 49 alemtuzumab Campath 49 Phase 2b clinical trials 49 Sular formulation 49 PMA submission 49 noninfectious uveitis 49 IMA# 49 BST CarGel R 49 hoFH 49 NABTT 49 hypercalcemia 49 Ceplene TM 49 Nasulin 49 TASKi2 49 PORxin TM platforms 49 MADIT CRT trial 49 EOquin TM 49 ganaxolone 49 Trofex ™ 49 liver transplant recipients 49 coronary stenting 49 UVIDEM 49 OvaRex 49 Vectibix panitumumab 49 CINTREDEKIN BESUDOTOX 49 bosutinib 49 Alzhemed TM 49 TAXUS Liberte Stent 49 curative resection 49 AzaSite Plus 49 VA# [002] 48 ospemifene 48 lintuzumab 48 betrixaban 48 preterm newborns 48 Neurostep TM 48 Aurexis 48 Trofex TM 48 REALITY Trial 48 enoximone 48 5-fluorouracil/leucovorin 48 FAME Study 48 Excellarate TM 48 romidepsin 48 heavily pretreated 48 multicentre randomized 48 picoplatin 48 chills fever headache 48 CRLX# 48 CRx 48 R# #mg BID 48 Epigenomics proprietary 48 axitinib 48 Zytiga 48 DPX Survivac 48 PrevOnco 48 remission CR 48 phase III isavuconazole 48 mapatumumab 48 Iluvien ® 48 macrovascular events 48 Secondary endpoints 48 blinatumomab 48 aflibercept 48 cytoreductive nephrectomy 48 ALN PCS 48 including eniluracil ADH 48 relapsed MM 48 prospective multicenter randomized 48 TOCOSOL Camptothecin 48 sorafenib Nexavar 48 hypercholesterolemic patients 48 EDEMA3 48 Linjeta TM 48 TMC# C# 48 EGS# 48 Fablyn 48 torsemide ER 48 Maximum Tolerated Dose MTD 48 diarrhea predominant irritable 48 Sepracor anticipates 48 urocortin 2 48 F FDG PET 48 unblinded 48 ALN TTR# 48 randomized trials 48 adjuvant therapies 48 Initiated Phase 48 Gabapentin GR 48 tremelimumab 48 postmarketing surveillance 48 ACCORD Lipid 48 blinded randomized 48 metastatic RCC 48 Neo Kidney Augment ™ 48 metastatic HRPC 48 DAPT 48 MEK inhibitor RDEA# 48 PHX# 48 SAR# [004] 48 custirsen 48 Hydroxyurea 48 Thalomid ® 48 tesmilifene Phase III 48 attain statistical significance 48 treatment naive genotype 48 Sorafenib HCC Assessment 48 MIRCERA 48 evaluating mipomersen 48 BrachySil 48 cangrelor 48 ReN# therapy 48 INS# [001] 48 IIa clinical trial 48 Panzem R NCD 48 pradefovir 48 Triapine R 48 elacytarabine 48 tumor resection 48 Riquent 48 Trovax 48 PROSTVAC TM 48 alemtuzumab MS 48 cetrorelix pamoate 48 Relivar 48 tumor histology 48 label multicenter 48 MDRD equation 48 Dalbavancin 48 mg/m2 dose 48 microbiologically evaluable 48 Phase III ADT 48 ThGRF 48 assessing T DM1 48 Deferiprone 48 prospectively stratified 48 paclitaxel poliglumex 48 INCB# [002] 48 ABRAXANE TM 48 Zemiva TM Trofex TM 48 randomized Phase III 48 Zavesca R 48 statistical significance p 48 GVAX 48 liprotamase 48 Raptiva R 48 Randomized Phase 48 Veronate 48 atrasentan 48 RezularTM 48 ALN VSP Phase 48 multicentre 48 anemia neutropenia 48 clinical 48 ongoing Phase 1b 48 AIR CF1 48 GLP toxicology 48 Allovectin 7 r 48 Memryte 48 GLPG# 48 CoFactor 48 abnormal glucose tolerance 48 GAP #B# 48 metastatic castration resistant 48 HF hospitalization 48 Zavesca r 48 squalamine 48 pertuzumab 48 viral kinetic 48 Velcade bortezomib 48 vaso occlusive crisis 48 unique alkylating agent 48 Chrysalin 48 CR# vcMMAE 48 Zoraxel 48 multicenter 48 pivotal Phase 48 multicenter randomized placebo controlled 48 multicenter randomized 48 CORLUX CORT # 48 Phase lll 48 platinum refractory 48 BLOOM DM 48 velaglucerase alfa 48 non alcoholic steatohepatitis 48 Prodarsan ® 48 relapsed AML 48 atacicept 48 Acute myeloid leukemia AML 48 oral prodrug 48 HuMax CD4 48 novel oral anticoagulant 48 Soliris TM eculizumab 47 PRTX 47 Synavive 47 Pafuramidine 47 therapeutic regimens 47 Cannabinor 47 Septin9 47 Drug Eluting Stent System 47 IFRS changeover 47 JP-#/fipamezole 47 drug PTK ZK 47 hepatocellular carcinoma liver